Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials

被引：0

作者：

Verma, S. ^{[1
,2
]}

Bain, S. C. ^{[3
]}

Bhatt, D. L. ^{[4
,5
]}

Leiter, L. A. ^{[1
,2
]}

Mazer, C. D. ^{[1
,2
]}

McGuire, D. K. ^{[6
]}

Pratley, R. ^{[7
]}

Zinman, B. ^{[8
]}

Lindberg, S. ^{[9
]}

Rasmussen, S. ^{[9
]}

Vrazic, H. ^{[9
]}

Buse, J. B. ^{[10
]}

机构：

[1] St Michaels Hosp, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

[3] Swansea Univ, Inst Life Sci, Swansea, W Glam, Wales

[4] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[7] AdventHlth Translat Res Inst Metab & Diabet, Orlando, FL USA

[8] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada

[9] Novo Nordisk AS, Soborg, Denmark

[10] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA

来源：

DIABETOLOGIA | 2019年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1164

引用

页码：S560 / S560

页数：1

共 50 条

[21] Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
Nauck, Michael A.
Quast, Daniel R.
[J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 12
[22] Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials
Zinman, B.
Verma, S.
Bain, S. C.
Honore, J. B.
Mann, J.
Nauck, M. A.
Pratley, R.
Rasmussen, S.
Ripa, M. Sejersten
Buse, J. B.
[J]. DIABETOLOGIA, 2019, 62 : S365 - S366
[23] IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN-6 CLINICAL TRIALS
Verma, Subodh
Bain, Stephen C.
Honore, Julie Broe
Mann, Johannes F. E.
Nauck, Michael A.
Pratley, Richard E.
Rasmussen, Soren
Ripa, Maria Sejersten
Zinman, Bernard
Buse, John
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1687 - 1687
[24] Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials
Kaul, Sanjay
[J]. DIABETES CARE, 2017, 40 (07) : 821 - 831
[25] Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Williams, David M.
Nawaz, Asif
Evans, Marc
[J]. DIABETES THERAPY, 2020, 11 (02) : 369 - 386
[26] Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams
Asif Nawaz
Marc Evans
[J]. Diabetes Therapy, 2020, 11 : 369 - 386
[27] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials
Verma, Subodh
David, Jens-Peter
Leiter, Lawrence A.
Michelsen, Marie Mide
Rasmussen, Soren
Bhatt, Deepak L.
[J]. DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
[28] Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials
Verma, Subodh
Leiter, Lawrence A.
Michelsen, Marie M.
Orsted, David
Rasmussen, Soren
Bhatt, Deepak L.
[J]. CIRCULATION, 2020, 142
[29] Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial
Zinman, B.
Verma, S.
Bhatt, D. L.
Bain, S. C.
Mann, J.
Nauck, M. A.
Pratley, R. E.
Michelsen, M. M.
Fries, T. Monk
Rasmussen, S.
Leiter, L. A.
[J]. DIABETOLOGIA, 2018, 61 : S555 - S556
[30] The importance of addressing multiple risk markers in type 2 diabetes: results from LEADER and SUSTAIN 6
Zobel, E. Hein
von Scholten, B. J.
Hansen, T. W.
Persson, F.
Rasmussen, S.
Wolthers, B.
Rossing, P.
[J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 5 - 6

← 1 2 3 4 5 →